Literature DB >> 15937348

Image analysis and data management of ELISPOT assay results.

Paul Viktor Lehmann1.   

Abstract

The recent renaissance of enzyme-linked immunospot (ELISPOT) assays largely is the result of advances in image analysis. Information on the frequency of antigen-specific T-cells and also on the secretion rate of the individual cells is captured in spots generated using this technique. Although the overall assessment of ELISPOT results can be conducted visually, this is inevitably subjective, inaccurate, and cumbersome. In contrast, objective, and accurate measurements are fundamental to good science. Validated image analysis algorithms and procedures, therefore, have become critical for elevating the quality of ELISPOT assays results. As cytokine and granzyme B ELISPOT assays become the gold standard for monitoring antigen-specific T-cell immunity in clinical trials, the pressure increases to make ELISPOT analysis transparent, reproducible and tamperproof, complying with Good Laboratory Practice and Code for Federal Regulations Part 11 guidelines. In addition, ELISPOT assays in clinical and basic science settings frequently require high degrees of throughput, thus further raising the need for advanced data management and statistical analysis. The ImmunoSpot software portfolio has been specifically designed to meet all these needs, using the techniques described in this chapter.

Mesh:

Substances:

Year:  2005        PMID: 15937348     DOI: 10.1385/1-59259-903-6:117

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  11 in total

1.  Multiplexed Elispot assay.

Authors:  William D Harriman; Ellen J Collarini; Remy G Cromer; April Dutta; Magnus Strandh; Fen Zhang; Lawrence M Kauvar
Journal:  J Immunol Methods       Date:  2008-12-11       Impact factor: 2.303

2.  Serial Measurements of Apoptotic Cell Numbers Provide Better Acceptance Criterion for PBMC Quality than a Single Measurement Prior to the T Cell Assay.

Authors:  Marie Wunsch; Richard Caspell; Stefanie Kuerten; Paul V Lehmann; Srividya Sundararaman
Journal:  Cells       Date:  2015-01-09       Impact factor: 6.600

3.  High Reproducibility of ELISPOT Counts from Nine Different Laboratories.

Authors:  Srividya Sundararaman; Alexey Y Karulin; Tameem Ansari; Nadine BenHamouda; Judith Gottwein; Sreenivas Laxmanan; Steven M Levine; John T Loffredo; Stephanie McArdle; Christine Neudoerfl; Diana Roen; Karina Silina; Mackenzie Welch; Paul V Lehmann
Journal:  Cells       Date:  2015-01-09       Impact factor: 6.600

4.  Resting of Cryopreserved PBMC Does Not Generally Benefit the Performance of Antigen-Specific T Cell ELISPOT Assays.

Authors:  Stefanie Kuerten; Helena Batoulis; Mascha S Recks; Edith Karacsony; Wenji Zhang; Ramu A Subbramanian; Paul V Lehmann
Journal:  Cells       Date:  2012-07-30       Impact factor: 6.600

5.  Optimal thawing of cryopreserved peripheral blood mononuclear cells for use in high-throughput human immune monitoring studies.

Authors:  Hari Ramachandran; Jessica Laux; Ioana Moldovan; Richard Caspell; Paul V Lehmann; Ramu A Subbramanian
Journal:  Cells       Date:  2012-07-25       Impact factor: 6.600

6.  The ADAMTS131239-1253 peptide is a dominant HLA-DR1-restricted CD4+ T-cell epitope.

Authors:  Laurent Gilardin; Sandrine Delignat; Ivan Peyron; Mathieu Ing; Yu-Chun Lone; Bagirath Gangadharan; Baptiste Michard; Yousra Kherabi; Meenu Sharma; Anastas Pashov; Jean-Baptiste Latouche; Mohamad Hamieh; Olivier Toutirais; Pascale Loiseau; Lionel Galicier; Agnès Veyradier; Srini Kaveri; Bernard Maillère; Paul Coppo; Sébastien Lacroix-Desmazes
Journal:  Haematologica       Date:  2017-07-27       Impact factor: 9.941

7.  Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology.

Authors:  Hideaki Tahara; Marimo Sato; Magdalena Thurin; Ena Wang; Lisa H Butterfield; Mary L Disis; Bernard A Fox; Peter P Lee; Samir N Khleif; Jon M Wigginton; Stefan Ambs; Yasunori Akutsu; Damien Chaussabel; Yuichiro Doki; Oleg Eremin; Wolf Hervé Fridman; Yoshihiko Hirohashi; Kohzoh Imai; James Jacobson; Masahisa Jinushi; Akira Kanamoto; Mohammed Kashani-Sabet; Kazunori Kato; Yutaka Kawakami; John M Kirkwood; Thomas O Kleen; Paul V Lehmann; Lance Liotta; Michael T Lotze; Michele Maio; Anatoli Malyguine; Giuseppe Masucci; Hisahiro Matsubara; Shawmarie Mayrand-Chung; Kiminori Nakamura; Hiroyoshi Nishikawa; A Karolina Palucka; Emanuel F Petricoin; Zoltan Pos; Antoni Ribas; Licia Rivoltini; Noriyuki Sato; Hiroshi Shiku; Craig L Slingluff; Howard Streicher; David F Stroncek; Hiroya Takeuchi; Minoru Toyota; Hisashi Wada; Xifeng Wu; Julia Wulfkuhle; Tomonori Yaguchi; Benjamin Zeskind; Yingdong Zhao; Mai-Britt Zocca; Francesco M Marincola
Journal:  J Transl Med       Date:  2009-06-17       Impact factor: 5.531

8.  Defining ELISpot cut-offs from unreplicated test and control wells.

Authors:  Neal Alexander; Annette Fox; Vu Thi Kim Lien; Tao Dong; Laurel Yong-Hwa Lee; Nguyen Le Khanh Hang; Le Quynh Mai; Peter Horby
Journal:  J Immunol Methods       Date:  2013-03-07       Impact factor: 2.303

9.  How much of virus-specific CD8 T cell reactivity is detected with a peptide pool when compared to individual peptides?

Authors:  Wenji Zhang; Ioana Moldovan; Oleg S Targoni; Ramu A Subbramanian; Paul V Lehmann
Journal:  Viruses       Date:  2012-10-29       Impact factor: 5.048

10.  Characterization of the HCMV-Specific CD4 T Cell Responses that Are Associated with Protective Immunity.

Authors:  Marie Wunsch; Wenji Zhang; Jodi Hanson; Richard Caspell; Alexey Y Karulin; Mascha S Recks; Stefanie Kuerten; Srividya Sundararaman; Paul V Lehmann
Journal:  Viruses       Date:  2015-08-06       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.